Bayer has joined forces with world-class academic institutions and other pharma companies as part of the Structural Genomics Consortium (SGC): In an Open Science effort we identify chemical probes for novel drug discovery targets and make them openly available for academic labs. They are able to use these probes without any restrictions to study the disease relevance of such novel targets. This joint effort is for the benefit of patients as high quality science forms the basis for the next generation of therapeutics.
Who this is for
Academia
Research institutes
What it’s about
Provision of chemical probes for further research to academic labs
We offer
Target name
Probe name
Probe negative pair
Literature reference
HNE
BAY-678
(S)-enantiomer is inactive
Potent and Selective Human Neutrophil Elastase Inhibitors with Novel Equatorial
Ring Topology: in vivo Efficacy of the Polar Pyrimidopyradazine BAY-8040 in a Pulmonary Arterial
Hypertension Rat Model. ChemMedChem 11(2): 199-206
SMYD2
BAY-598
BAY-369
Discovery and Characterization of a Highly Potent and Selective
Aminopyrazoline-Based in Vivo Probe (BAY-598) for the Protein Lysine Methyltransferase SMYD2. Journal of
Medicinal Chemistry, 59(10): 4578-600
BRPF2/TAF1L
BAY-299
BAY-364
Benzoisoquinolinediones as Potent and Selective Inhibitors of BRPF2 and
TAF1/TAF1L Bromodomains. Journal of Medicinal Chemistry, 60(9): 4002–4022
ATAD2
BAY-850
BAY-460
Isoform-Selective ATAD2 Chemical Probe with Novel Chemical Structure and Unusual
Mode of Action ACS Chem. Biol., 12 (11): 2730-2736
GLUT1
BAY-876
BAY-588
Identification and Optimization of the First Highly Selective GLUT1 Inhibitor
BAY-576. ChemMedChem 11(29): 2261-2271
MTH1
BAY-707
BAY-604
Novel Class of Potent and Cellularly Active Inhibitors Devalidates MTH1 as
Broad-Spectrum Cancer Target. ACS Chem Biol. 2017 Aug 18;12(8):1986-1992
SMYD3
BAY-6035
BAY-211
MMP12
BAY-7598
BAY-694
PAR1
BAY-386
BAY-448
cMET
BAY-474
BAY-827
Tie/DDR
BAY-826
BAY-309
Submission deadlines
No submission deadlines. Please contact us any time.
Your contacts:
Cora Scholten
Pharmaceuticals Research & Development External Innovation & Alliances
